Status and phase
Conditions
Treatments
About
The purpose of this study is to optimize therapy according to the known risk factors and treatment response in pediatric acute myeloid leukemia (AML)
Full description
I. Risk group assessment Favorable prognosis group: Low risk features + Good response
Intermediate prognosis group:
Poor prognosis group:
II. Chemotherapy Induction-1: Cytarabine + idarubicin Induction-2: High dose (HD) cytarabine + mitoxantrone Consolidation-1: Cytarabine + idarubicin Consolidation-2: HD cytarabine + etoposide Consolidation-3: HD cytarabine + mitoxantrone Consolidation-4: HD cytarabine + etoposide
III. Allogeneic hematopoietic stem cell transplantation (HSCT) Favorable prognosis group: chemotherapy only Intermediate prognosis group: chemotherapy or HSCT with reduced intensity conditioning Poor prognosis group: HSCT with myeloablative conditioning
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
350 participants in 1 patient group
Loading...
Central trial contact
Keon Hee Yoo, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal